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ABSTRACT
Predicting and discovering drug-drug interactions (DDIs) is an im-
portant problem and has been studied extensively both from medical
and machine learning point of view. Almost all of the machine learn-
ing approaches have focused on text data or textual representation of
the structural data of drugs. We present the first work that uses drug
structure images as the input and utilizes a Siamese convolutional
network architecture to predict DDIs.
CCS CONCEPTS
• Deep Learning→ Siamese Neural Networks; • Application→
Healthcare; • Healthcare→ Drug-Drug Interaction.
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1 INTRODUCTION
Adverse drug events (ADEs) are “injuries resulting from medical
intervention related to a drug” [43], and are distinct from medication
errors (inappropriate prescription, dispensing, usage etc.) as they
are caused by drugs at normal dosages. According to the National
Center for Health Statistics [42], 48.9% of Americans took at least
one prescription drug in the last 30 days, 23.1% took at least three,
and 11.9% took at least five. These numbers rise sharply to 90.6%,
66.8% and 40.7% respectively, among older adults (65 years or
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older). This means that the potential for ADEs is very high in a
variety of health care settings including inpatient, outpatient and
long-term care settings. For example, in inpatient settings, ADEs can
account for as many as one-third of hospital-related complications,
affect up to 2 million hospital stays annually, and prolong hospital
stays by 2–5 days [21].
The economic impact of these issues is as widespread as the
various healthcare settings and can be staggering. Estimates suggest
that ADEs contributed to $3.6 billion in excess healthcare costs in
the US alone [4]. Unsurprisingly, older adults are at the highest
risk of being affected by an ADE, and are seven times more likely
than younger persons to require hospital admission [11]. In the US,
as a large number of older adults are Medicare beneficiaries, this
economic impact is borne by an already overburdened Medicare
system and ultimately passed on to taxpayers and society at large.
Beyond older adults, there are several other patient populations
that are also vulnerable to ADEs including children, those with
lower socio-economic means, those with limited access to healthcare
services, and certain minorities.
Recent research has identified, somewhat surprisingly, that many
of these ADEs can be attributed to very common medications [10]
and many of them are preventable [27] or ameliorable [23]. This
issue motivates our long-term goal of developing accessible and
robust means of identifying ADEs in a disease/drug-agnostic man-
ner and across a variety of healthcare settings. Here, we focus on
the problem of drug-drug interactions (DDIs), which are a type
of ADE. An ADE is characterized as a DDI when multiple medica-
tions are co-administered and cause an adverse effect on the patient.
DDIs, often caused by inadequate understanding of various drug-
drug contraindications, are a major cause of hospital admissions,
rehospitalizations, emergency room visits, and even death [5].
Predicting and discovering drug-drug interactions (DDIs) is an
important problem and has been studied extensively both from med-
ical and machine learning point of view. Identifying DDIs is an
important task during drug design and testing, and regulatory agen-
cies such as the U. S. Food and Drug Administration require large
controlled clinical trials before approval. Beyond their expense and
time-consuming nature, it is impossible to discover all possible in-
teractions during such clinical trials. This necessitates the need for
computational methods for DDI prediction. A substantial amount of
work in DDI focuses on text-mining [12, 40] to extract DDIs from
large text corpora; however, this type of information extraction does
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Figure 1: Some example molecular images of different drugs extracted from the PubChem database.
not discover new interactions, and only serves to extract in vivo or
in vitro discoveries from publications.
Our goal is to discover DDIs in large drug databases by exploit-
ing various properties of the drugs and identifying patters in drug
interaction behaviors. Almost all of the machine learning approaches
have focused on text data or textual representation of the structural
data of drugs [3, 26, 46]. Recent approaches consider phenotypic,
therapeutic, structural, genomic and reactive properties of drugs [14]
or their combinations [20] to characterize drug interactivity. We take
a fresh and completely new perspective on DDI prediction through
the lens of molecular images, a few examples shown in figure 1, via
deep learning. Our work is novel in the following significant ways:
• we formulate DDI discovery as a link prediction problem;
• we aim to perform DDI discovery directly on molecular
structure images of the drugs directly, rather than on lossy,
string-based representations such as SMILES strings and
molecular fingerprints; and
• we utilize a deep learning technique, specifically Siamese
networks [16] in a contrastive manner to build a DDI dis-
covery engine that can be integrated into a drug database
seamlessly.
2 RELATEDWORK
2.1 Drug-Drug Interactions
The social and economic impacts of drug-drug interactions have also
been well studied and understood. The effect of DDI on medication
management and social care is studied in [2] and with its economic
impact shown in [52]. The impact of DDIs in the elderly patients
in 6 Europen countries was documented in [7] and in a similar vein
the study by Becker et al. [5] identifies that the elderly have an
increased risk factor ≈ 9 times over the general population with
the clinical significance of DDIs studied in [48]. Identification of
DDIs can be done by either clinical trials or in vitro and in vivo
experiments but these approaches are highly labor-intensive, costly
and time-consuming. Thus, a system that can mitigate these factors
is highly desirable.
Drug-Drug interactions have been studied extensively both from
medical and machine learning point of view. From a medical stand-
point [39], [30] and [56] showed the effect of important individual
drugs and enzymes such as subtrates on various drug-drug interac-
tions. The problem of DDI discovery/prediction is a pairwise clas-
sification task and thus kernel-based methods [53] are a natural fit
since kernels are naturally suited to representing pairwise similarities.
Most similarity-based methods for DDI discovery/prediction have
used biomedical research literature as the underlying data source
and construct NLP-based kernels from these medical documents
[17, 51]. Some work has also been done on learning kernels from
different types of data such as molecular and structural properties
of the drugs and then using these multiple kernels to predict DDIs
[14, 20].
2.2 Siamese Neural Networks
Siamese networks have been applied in one shot image recogni-
tion [37], signature verification [9], object tracking [6] and human
re-identification [18, 54]. Siamese networks have also been used
in the health care domain in medical question retrieval [55] and
Alzheimer disease diagnosis [1]. Siamese networks have also been
used for the tasks of drug-drug interactions in the form of a Siamese
graph convolutional network [13, 33].
3 SIAMESE CONVOLUTIONAL NETWORK
FOR DRUG-DRUG INTERACTIONS
A discriminative approach for learning a similarity metric using a
Siamese architecture was introduced in [16] which maps the input
(pair of images in our case) into a target space such that the distance
between the mappings is minimized in the target space for similar
pair of examples and maximized in case of dissimilar examples. We
adapt the Siamese architecture for the task of link prediction where
the link is whether two drugs interact or not. Since the Siamese
architecture results in a measure of similarity between the pair of
given inputs it can be thresholded in order to obtain a classification.
We use contrastive loss [28], based on a distance metric (Euclidean
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Figure 2: An overview of our model for predicting drug-drug interactions
distance in our case), to learn a parameterized function F to obtain the
mapping from the input space to the target space whose minimization
can result in pushing the semantically similar examples together.
An important property of the loss function is that it calculated on
a pair of examples. The loss function is formulated as as follows:
Let X1 and X2 are a pair of drug images and Y is the label assigned
to each of the pairs. The label Y = 0 if the pair of drug images do
not interact and Y = 1 if the pair of drug images interact. Also, let
D be the Euclidean distance between the vector of the image pairs
after being processed by the underlying Siamese network and P are
the parameters of the function F. The contrastive loss function can
then be given as
L(P ,X1,X2,Y ) = (1 − Y )2 DP
2 +
Y
2 {max(0,m − DP )}
2 (1)
where DP = ∥FP (X1) − FP (X2)∥22 is the Eucledian distance between
the obtained outputs after the input pairs are processed by the sub-
networks. Also m is a margin such that m ≥ 0 that signifies that
dissimilar pairs beyond this margin will not contribute to the loss.
Figure 2 shows our complete architecture. It consists of two
identical sub-networks i.e. networks having same configuration with
the same parameters and weights. Each sub-network takes a gray-
scale image of size 500 × 500 × 1 as input (we initially have color
images that we convert to gray-scale before feeding to sub-networks
as input) and consists of 4 convolutional layers with number of
filters as 64, 128, 128 and 256 respectively. The kernel size for each
convolutional layer is (9 × 9) and the activation function is relu. The
relu is a non-linear activation function is given as f (x) =max(0,x).
Each convolutional layer is followed by a max-pooling layer with
pool size of (3 × 3) and a batch normalization layer. After the
convolutional layers, the sub-network has 3 fully connected layers
with 256, 128 and 20 neurons respectively. Thus after an image pair
is processed by the Siamese sub-networks two vectors of dimension
20 × 1 are obtained. Contrastive loss is then applied to the obtained
pair of vectors to obtain a distance between the input pair which can
then be thresholded to obtain a prediction.
Figure 3: An example of how two isomers interact differently
with a single drug.
Bangalore ’21, January 02–04, 2021, Bangalore, India Dhami et al.
Figure 4: Using spatial transformer network as a pre-processing step to mitigate rotational variance. Note that this process is done
for both the input images.
We use the technique of precision recall curve (PR-curve) to iden-
tify the best threshold = 0.65. Note that the convolutions in the con-
volutional sub-network provide translational in-variance property but
rotational in-variance is also important in our problem domain. This
is because isomers (one of the chiral forms) of drugs are expected to
react differently when interacting with a certain drug [15, 45]. For
example, Fenfluramine and Dexfenfluramine are isomers of each
other and where Fenfluramine interacts with Acebutolol but Dexfen-
fluramine does not (Figure 3). Another example is that the L-isomer
of methorphan, Levomethorphan, is an opioid analgesic, while the
D-isomer, Dextromethorphan, is a dissociative cough suppressant1.
To overcome this problem and introduce rotational invariance into
our framework, we make use of spatial transformer networks [32]
that we discuss next.
3.1 Spatial Transformer Networks
Spatial Transformer Network (STN) is a visual attention mechanism
that can handle the scaling and rotation of the input images to the
underlying convolutional network thereby leading to a better perfor-
mance by reducing the effect of the rotation variance, which is a hard
problem for convolutional neural networks [19]. It consists of three
basic building blocks: a localisation network, a grid generator and
a sampler which can be used as a pre-processing step before feed-
ing the input image pair into our underlying Siamese architecture
as shown in Figure 4. The whole network is differentiable, which
means that it can be plugged directly into an existing model. The
localisation network is used to regress the transformation parameters
θ , which controls the rotation, translation, zooming in and zooming
out of the input images.
The localisation network takes the input image, say X1 in our
case, and generates θ = floc (X1) that can then be used to calculate
the target image Xˆ1 . There is no specific requirement for the locali-
sation network except it should be able to generate regression value
for θ . Our localization network is a convolutional neural network
consisting of 2 pooling layers, 2 convolutional layers and 2 dense
layers. The transformation parameters θ is the mapping between
source image coordinators
(
xX1i ,y
X1
i
)
and target image coordinators(
x Xˆ1i ,y
Xˆ1
i , 1
)
as shown by the equation 2. Note that transformation
1https://en.wikipedia.org/wiki/Enantiopure_drug
function is not learned explicitly rather is learned automatically by
the network.
(
xX1i
yX1i
)
=
[
θ11 θ12 θ13
θ21 θ22 θ23
] ©­­«
x Xˆ1i
yXˆ1i
1
ª®®¬ (2)
Hence, the localization and transformation as shown in Figure
4 are done in a single step. For the sampling kernel, we used the
standard bilinear interpolation as described in [32], since gradients
can be defined with respect to the source image coordinates for
bilinear interpolation.
4 EXPERIMENTS
We aim to answer the following questions:
Q1: Are Siamese networks effective in link prediction task
of DDI?
Q2: What is the effect of number of epochs on the predictive
performance of the Siamese architecture?
Q3: Does our architecture handle the problem of rotational
variance?
Q4: Are molecular structure images informative enough to
predict DDIs and can be used instead of lossy string represen-
tations?
Q5: How does our method compare with state-of-the-art sta-
tistical relational models?
Q6: How does the choice of distance function for contrastive
loss effect the prediction performance?
Q7: How does the choice of optimization function effect the
prediction performance?
4.1 Data set
Our data set consists of images of 373 drugs of size 500 × 500 ×
3 downloaded from the PubChem database 2 and converted to a
grayimage format to yield images of size 500 × 500 × 1. From these
images we create a total of 67,360 drug interaction pairs excluding
the reciprocal pairs (Since drug-drug interaction is reciprocal in
nature i.e. if drug d1 interacts with drug d2 then d2 interacts with d1
and vice versa, we need to remove such pairs from our data). From
2https://pubchem.ncbi.nlm.nih.gov/
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the 67,630 drug pairs we obtain a data set of 19936 drug pairs that
interact with each other (Y = 1) and 47424 drug pairs that do not
interact with each other (Y = 0). The images are normalized by the
maximum pixel value (i.e. 255) before passing to the network. The
data set and the code is available at https://rb.gy/koax5u.
Figure 5: An example of abstract features learned by a convolu-
tional layer for Venlafaxine.
4.2 Baselines
We consider 5 baselines using different data modalities to compare
the results from our Siamese architecture, namely,
(1) Image data:
1. Structural Similarity Index (SSIM): is used for measur-
ing perceptual similarity between images [57] and given 2
images X1 and X2 is calculated as,
SSIM(X1,X2) =
(2µX1µX2 +C1) × (2σX1X2 +C2)
(µ2X1 + µ2X2 +C1) × (σ 2X1 + σ 2X2 +C2)
(3)
where µX1 and µX2 is the average of the images X1 and X2
respectively, σX1 and σX2 is the variance of the images X1
and X2 respectively, σX1X2 is the covariance of the two input
images. The constants C1 and C2 are added to the SSIM to
avoid instability and are the product of a small constant (≪
1) with the dynamic range of pixel values in the given im-
ages. The SSIM measure can also be written as the product
of three types of comparisons between input images, namely,
luminance, contrast and structure. To obtain the predictions,
the SSIM needs to be thresholded and in the experiments, the
threshold is set as the mean SSIM values of all pairs.
2. Autoencoders: are neural networks that consists of 2 main
components: an encoder and a decoder [38]. The encoder
extracts features from the input images and decoder restores
the original images from the extracted features. In general,
the performance of autoencoders are evaluated by pixel-wise
comparison between input images and output images. In order
to compare the similarity between two images, the similarity
between extracted features of the two images can be com-
pared. This approach should be able to find images which
contain objects with similar color and shape.
For the encoder, we have three convolutional layers with filter
sizes 16, 32 and 64 followed by a max pooling layer which
is in turn followed by two convolutional layers with filter
sizes 128, 64 and another max pooling layer. The final three
convolutional layers consists of filters of sizes 32, 16 and
8. For the decoder, we have two convolutional layers with
filter sizes 16 and 32 followed by a single up-sampling layer
which is in turn followed by two convolutional layers with
filter sizes 64 and 128 again followed by a single up-sampling
layer. The final four convolutional layers consists of filters of
sizes 64, 32, 16 and 1. The size of all kernels is 3×3. The size
of max pooling is 2×2 and up sampling size is also 2×2. The
activation of all convolutional layers is relu, except the last
layer of both encoder and decoder is a sigmoid, for the ease
of comparison.
First, the autoencoder model is trained using the training
images, as is the normal training process of an autoencoder
model. The number of epochs is 10 and the loss function is
binary cross-entropy. Then features are extracted using the
encoder on the testing images. To find images with similar
extracted features, a couple of criterion were used, namely,
binary cross-entropy and cosine proximity. The threshold to
decide whether the two images is similar or not was set as the
mean of all values calculated for all pairs of testing image.
(2) String data:
1. CASTER [31] uses the drug molecular structure in a text
format of Simplified Molecular Input Line Entry System
(SMILES) [58] strings representation to predict drug-drug
interactions and ouperforms several deep learning methods
such as DeepDDI [49] and molVAE [25]. CASTER identifies
the frequent substrings present in the SMILES strings pre-
sented during the training phase using a sequential pattern
mining algorithm which are then converted to a emdedded
representation using an encoder module to obtain a set of
latent feature vectors. These features are then converted into
linear coefficients which are then passed through a decoder
and a predictor to obtain the DDI predictions. We obtain the
SMILES strings of all the drugs in our data set from PubChem
and DrugBank 3 and use the source code 4 provided by the
authors along with provided default hyper parameter settings.
(3) Relational Data:
1. RDN-Boost [41] extends the functional gradient boosting
framework [24] to the relation setting by boosting relational
dependency networks (RDNs) [44] with the aim to overcome
the assumption of a propositional representation of the data
as in standard functional gradient boosting. The objective
function used in is the log-likelihood and probability of an ex-
ample is represented as a sigmoid over the learned relational
regression trees (RRT) [8] which uses the relational features
as input. The basic idea is to take an initial model (RRT)
and use the obtained predictions to compute gradient(s) or
residues. A new regression function i.e. a new RRT is then
learnt to fit the residues and the model is updated. At the
end, a combination (the sum) of all the obtained regression
function gives the final model.
3https://www.drugbank.ca/
4https://github.com/kexinhuang12345/CASTER
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2. MLN-Boost [34] boosts the undirected Markov logic net-
works (MLNs) [47] instead of the directed relational depen-
dency networks in case of RDN-Boost. In MLN-Boost the
structure and parameters of the MLN are learned simultane-
ously by converting the problem of learning MLNs to a series
of relational functional approximation problems similar to
the RDN-Boost setting, with the only difference being that
the number of groundings for each learned clause are counted
in case of MLN-Boost whereas RDN-Boost uses existential
semantics.
We convert the data obtained from DrugBank to the relational for-
mat with number of relations = 14 and the total number of facts =
5366. For both RDN-Boost and MLN-Boost we set the number of
relational regression trees to be learned as 10.
4.3 Results
We optimize our Siamese network using the Adam as the optimiza-
tion algorithm [35] with a learning rate of 5× 10−5 (we also train the
network using several other optimization algorithms as defined later).
The best learning rate was obtained using line search. We set the
value of the marginm in contrastive loss equal to 1. As mentioned
before, we keep the threshold value as 0.65, obtained using AUC-PR
curve, to obtain the predictions after obtaining a distance between
pair of drug images using the Siamese convolutional network. We
divide our data set into 44457 training (66% of the data) and 22903
testing examples. Example features learned by the second convo-
lutional layer in our network for the drug Venlafaxine is shown in
figure 5. When pre-processing the data using a STN, we rotate the
data set images by 90° and pass it through the STN before passing
it through our Siamese network. Another important thing to note
here is that in our problem formulation recall is the most important
factor that should be considered. The simple reason is that we do
not want to miss any interaction i.e. a false negative results in much
more serious consequences (fatalities in patients) than false positives
(monetary losses such as new clinical trials) [20] although a recall
gain should not come at the cost of loss in precision since that can
be obtained simply by classifying every test example as a positive
example.
Figure 6 shows the results of using our Siamese network archi-
tecture with and without rotational invariance (STN) compared with
baselines. The Siamese network with and without STN (results here
reported for 50 epochs for both cases) outperforms the baselines
thereby answering Q1 affirmatively. Siamese networks are clearly
effective and significantly better for the DDI task of link prediction.
Note that although the recall of auto-encoders is higher than the
Siamese network, the very low precision shows a high rate of false
positives and thus its performance cannot be judged as being better
than the proposed model.
Figure 7 shows the variation of performance of Siamese network
(figure 7a) and Siamese network with STN (figure 7b) with respect to
the number of iterations. The results for Siamese networks without
STN do not show any significant change wrt the increasing epochs
across metrics whereas in case of Siamese networks with STN,
the results show a steady increase with increasing iterations across
majority of metrics. The recall decreases with increasing number of
epochs in both cases i.e Siamese networks with and without STN
Figure 6: Results for DDI prediction using images. Although
the recall of auto-encoders (AE) is higher than the Siamese net-
work, low precision shows a high rate of false positives.
but the decrease is more stark in case of the network without STN
whereas the drop is not significant in the other case with STN. This
answers Q2.
We refer back to figures 6 and 7 to answer Q3. The performance
of Siamese network with no STN is certainly better than with STN
especially in lesser number of epochs although the difference in
performance begins to shrink with the increase in the number of
epochs. This is expected since STN, being a separate convolutional
network in itself, takes longer number of epochs to train. Due to this
steady increase in performance of Siamese network with STN we
can answer Q3 affirmatively. Our architecture can effectively handle
the problem of rotational variance.
Figure 8 shows the result of our method when compared to a
recent state-of-the-art method, CASTER. Our method outperforms
CASTER across majority of metrics thereby proving the effective-
ness of our approach in identifying drug-drug interactions. We show
that using molecular structure images directly in a deep learning
framework can result in a better/on-par performance than using lossy
string based representations. This answers Q4.
Figure 9 shows the result of comparing our method (Siamese
network without STN trained for 50 epochs) to the state-of-the-art
statistical relational learning baselines. Our method outperforms
both the boosted methods across majority of the metrics. Note that
similar to the results obtained when comparing with image based
methods (figure 6), although the recall of MLN-Boost is higher than
the Siamese network, an accompanying low precision score shows
a higher rate of false positives. This shows that using the molecu-
lar structural images directly can result in a better link prediction
performance than using the data for the same drugs in a relational
setting. This answers Q5.
An ideal predictor can use all the heterogeneous data types of
the drugs considered i.e. images, string based representation and
relational representation. We propose an initial sketch of such a
model and leave it as future work. A graph convolutional network
(GCN) [36] is a type of graph neural network that extends the neural
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(a) Performance of Siamese network across epochs
(b) Performance of Siamese network with STN across epochs
Figure 7: Variation of DDI prediction of the proposed networks
wrt epochs.
network models to be principally applied on graph data sets. A
GCN makes use of a node feature matrix and the graph adjacency
matrix to propagate functional values akin to a neural network to
accomplish link prediction and node classification tasks. We propose
a heterogeneous GCN where heterogeneous data types available to
us can be used to obtain the feature and adjacency matrix to be fed
to the GCN. For example, relational data can be used to learn lifted
rules which can then be grounded and the counts of the satisfied
groundings can form a more richer and informed feature matrix
than simple node features. A combination of the distances between
the images and the string representation can form a more informed
adjacency matrix and we can solve the drug-drug interaction problem
as a link prediction problem.
All the above reported results use euclidean distance as the metric
to be used in contrastive loss while training the Siamese network
(DP in equation 1). To answer Q6 we use 3 more distance metrics to
be used inside the contrastive loss. These metrics are:
Figure 8: Comparison of our method (using images) with
CASTER (using SMILES strings).
Figure 9: Comparison of our method (using images) with RDN-
Boost and MLN-Boost (using relational data).
(1) Manhattan distance: This is the 1 norm distance between
vectors i.e. the sum of absolute difference of the components
of the vectors and is defined as DP = |FP (X1) − FP (X2)|1.
(2) Hellinger distance: is a close relative of euclidean distance
and is used to find the distance between 2 probability distri-
butions. The Hellinger distance is given as
DP =
√
2
∑(√X1X¯1 −√X2X¯2 )2.
(3) Jaccard distance: can be calculated in between binary seg-
mentation of the input images and is given as DP =
|X1∩X2 |
|X1∪X2 | .
Table 1 shows the effect of using different distance metrics within
the contrastive loss on the performance of the Siamese architec-
ture (without STN). The results show that the use of euclidean and
Manhattan distance as the metric in the contrastive loss perform
similarly and outperform Hellinger and Jaccard distance by huge
margins. Although the recall values using Hellinger distance and
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Table 1: Effect of choice of distance metric on the prediction performance.
Distance Metric Number of Epochs Accuracy Recall Precision F1
Manhattan distance
20 0.817 0.849 0.645 0.733
30 0.828 0.866 0.665 0.752
50 0.806 0.828 0.634 0.718
Hellinger distance
20 0.300 1.0 0.297 0.461
30 0.297 1.0 0.297 0.458
50 0.295 1.0 0.295 0.456
Jaccard distance
20 0.703 0.01 0.427 0.02
30 0.703 0.0 0.7 0.0
50 0.703 0.0 1.0 0.0
Euclidean distance
20 0.822 0.835 0.657 0.735
30 0.832 0.849 0.669 0.748
50 0.839 0.78 0.705 0.741
Table 2: Effect of choice of optimization function on the prediction performance.
Optimization function Number of Epochs Accuracy Recall Precision F1 Score
RMSprop [29]
20 0.822 0.672 0.715 0.693
30 0.770 0.877 0.576 0.696
50 0.816 0.640 0.707 0.672
Adadelta [59]
20 0.721 0.138 0.667 0.229
30 0.827 0.813 0.672 0.735
50 0.851 0.831 0.707 0.764
Nadam [22]
20 0.812 0.852 0.639 0.730
30 0.828 0.833 0.668 0.742
50 0.848 0.790 0.721 0.754
Adam [35]
20 0.822 0.835 0.657 0.735
30 0.832 0.849 0.669 0.748
50 0.839 0.780 0.705 0.741
precision values using Jaccard distance, at 50 epochs, are perfect
i.e. equal to 1, the respective precision and recall values in both the
distances are very low thereby showing that using these distances in
the contrastive loss leads to poor performance. This answers Q6.
Table 2 shows the effect of using different optimization functions
(RMSProp, Adadelta and Nadam) to optimize the Siamese network
with increasing number of epochs. The last row in table 1 shows the
results with using Adam as the optimization function with increasing
number of epochs. We include that row in table 2 for more clarity.
The results vary widely with respect to the optimization function
used with an increase in the performance wrt the increasing number
of epochs in case of Adadelta [59] optimization function. In case of
the other 3 optimization functions, interestingly, we note that there
is a drop in recall when we go from 30 to 50 epochs. This shows that
the choice of the optimization function does play a big part in the
prediction performance thereby answering Q7.
5 CONCLUSION
In this work we focus on using the molecular images of the drugs in
a pairwise fashion and feeding them to a rotation-invariant Siamese
architecture to predict whether two drugs interact with each other.
Our evaluations on the drug images obtained from PubChem data-
base establish the superiority of our proposed approach, which is
distinct from current approaches that generally uses SMILES and
SMiles ARbitrary Target Specification (SMARTS) strings [50].
Combining our previous work [20] that used different similarity
measures obtained from a directed graph of known chemical reac-
tions between drugs and enzymes, transporters and inhibitors as well
as the structure of the drugs in the form of SMILES and SMARTS
strings and the current work which uses images of the drug structure
is a natural next step. Also refining the Siamese architecture and
feeding more drug images to the network are an interesting area of
future work.
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